Real-time Analyses of Retinol Transport by the Membrane Receptor of Plasma Retinol Binding Protein

Summary

Here we describe an optimized technique to produce high-quality vitamin A/RBP complex and two real-time monitoring techniques to study vitamin A transport by STRA6, the RBP receptor.

Abstract

Vitamin A is essential for vision and the growth/differentiation of almost all human organs. Plasma retinol binding protein (RBP) is the principle and specific carrier of vitamin A in the blood. Here we describe an optimized technique to produce and purify holo-RBP and two real-time monitoring techniques to study the transport of vitamin A by the high-affinity RBP receptor STRA6. The first technique makes it possible to produce a large quantity of high quality holo-RBP (100%-loaded with retinol) for vitamin A transport assays. High quality RBP is essential for functional assays because misfolded RBP releases vitamin A readily and bacterial contamination in RBP preparation can cause artifacts. Real-time monitoring techniques like electrophysiology have made critical contributions to the studies of membrane transport. The RBP receptor-mediated retinol transport has not been analyzed in real time until recently. The second technique described here is the real-time analysis of STRA6-catalyzed retinol release or loading. The third technique is real-time analysis of STRA6-catalyzed retinol transport from holo-RBP to cellular retinol binding protein I (CRBP-I). These techniques provide high sensitivity and resolution in revealing RBP receptor's vitamin A uptake mechanism.

Introduction

Vitamin A is an organic molecule that is essential for human survival and the proper functioning of almost all human organs. Vitamin A derivatives (retinoids) participate in diverse biochemical and cellular events including the sensing of light for vision ^1,2 and the regulation of gene expression and protein translation during embryonic development and in adult tissues ^3-6. Although retinol has the ability to diffuse systemically, evolution came up with plasma retinol binding protein, a specific carrier protein for vitamin A transport in the blood to achieve high efficiency and specificity and to avoid toxicity associated with random diffusion ^7-10. A high-affinity receptor that binds to RBP and takes up vitamin A was hypothesized in the 1970s ^11-13. Despite evidence accumulated in three decades on the existence of the RBP receptor ^14-31, the receptor hypothesis was debated for many years due to the existence of an incorrect definition of holo-RBP. The correct definition of holo-RBP is that it is the high affinity 1:1 complex between retinol and RBP. Repeated extraction of holo-RBP by organic solvent is necessary to produce apo-RBP. This definition is used by almost all labs studying RBP ^7,9,32-35 or the RBP receptor ^14-31,36-42. The incorrect definition of holo-RBP that was used to disprove the existence of the RBP receptor is the acute mixture of free retinol with apo-RBP. Since the function of the RBP receptor in vitamin A uptake from holo-RBP is to release retinol from holo-RBP, the RBP receptor would play no role in retinol uptake if retinol is free to begin with (as proposed by the incorrect definition of holo-RBP).

The recent identification of RBP receptor as a multitransmembrane domain protein called STRA636 and its function in vitamin A uptake from holo-RBP ^36-43 strongly argues against the hypothesis that RBP does not need a receptor to deliver vitamin A. Detailed analyses revealed that STRA6 has 9 transmembrane domains with the N-terminus located extracellularly and C-terminus located intracellularly ⁴⁰. Located between transmembrane 6 and 7 is an essential RBP binding domain ³⁹. STRA6 is coupled to both LRAT and CRBP-I in vitamin A uptake from holo-RBP, but neither LRAT nor CRBP-I is absolutely required for enhanced STRA6 activity ⁴¹. STRA6's ability to catalyze retinol release from holo-RBP is the key to its vitamin A uptake activity ⁴¹. By relying on STRA6 to release its retinol, vitamin A delivery by RBP can transport vitamin A to target cells in peripheral tissues with high specificity and efficiency.

The critical importance of holo-RBP definition and preparation is illustrated not only by the historical debate on the existence of the RBP receptor, but also by three related recent papers based on holo-RBP definitions different from the original and correct definition ^44-46. The first paper used the holo-RBP definition that was used to disapprove the existence of the RBP receptor to study the RBP receptor ⁴⁴. The second and third papers came up with a third definition of holo-RBP that made it even less likely for retinol to be studied to form a proper complex with RBP ^45,46. These studies prepared ³H-retinol/RBP by mixing holo-RBP (not even apo-RBP) with ³H-retinol. Since this assay did not have ³H-retinol/RBP formed and did not remove excessive free ³H-retinol ^45,46, it is not an assay for ³H-retinol uptake from ³H-retinol/RBP, but is a free ³H-retinol diffusion assay. It has been shown previously that STRA6 does not enhance cellular uptake of free retinol by LRAT ³⁸ or CRBP-I ⁴¹. Virtually all retinol is bound to RBP in the blood and there is no detectable free retinol. A main function of the RBP receptor is to catalyze retinol release from holo-RBP during retinol uptake from holo-RBP ⁴¹. If the retinol is artificially released or is in the free form to begin with ^45,46, the RBP receptor is not needed. The dramatically different results obtained from the free retinol diffusion assay as compared to assays based on correctly prepared holo-RBP illustrate that correct preparation of RBP is crucial for its functional assays.

RBP can be purified from human serum ⁴¹, but the procedure is complex and the yield is low. An alternative approach is to produce RBP in E. coli. Because E. coli does not have the ability to correctly fold mammalian secreted proteins with more than one pair of disulfide bonds like RBP, it is essential to refold RBP and purify the correctly folded protein. Misfolded proteins not only behave differently from corrected folded RBP in various assays, but also cause protein aggregation during storage. For the same reason, apo-RBP is only produced from high-quality holo-RBP. We describe here an optimized protocol to produce high quality RBP 100% loaded with retinol through bacterial expression, refolding, and HPLC purification. HPLC purification not only removes incorrectly folded RBP but also significant bacterial contamination that can cause serious artifacts if RBP is used in signal transduction assays. We also describe two sensitive real-time monitoring techniques to study retinol transport by STRA6. Both techniques depend on high quality RBP. Due to space limitations, the classic techniques of radioactive retinoid-based and HPLC-based vitamin A uptake assays are not described here.

Protocol

1. Production, Refolding, and HPLC Purification of Holo-RBP

1. Transform BL-21cells with the pET3a vector harboring the cDNA for human RBP with 6x His tag on the N-terminus. Grow the transformed BL-21 cells in a shaker at 37 °C in 40 ml LB media with carbenicillin until O.D. at 600 nm reaches 0.5. Induce RBP protein expression by adding IPTG to 1mM. Grow the bacteria at 37 °C another 5 hr.
2. RBP produced in E.coli is mostly present in insoluble inclusion bodies. To enrich inclusion bodies, pellet cells at 10,000 x g for 20 min. Then sonicate the cells on ice in 5 ml PBS with protease inhibitors, followed by 2 cycles of freezing and thawing. Pellet down the inclusion bodies at 20,000 x g for 30 min at 4 °C. Remove supernatant and keep the pellet on ice.
3. Solubilize the inclusion body pellet by sonication in 10 ml 7.5 M guanidine hydrochloride. Add a half volume (5 ml) of 25 mM Tris buffer, pH 9.0 and DTT to a final concentration of 10 mM. Vigorously mix solution on a vortex mixer overnight at room temperature to fully reduce and denature proteins.
4. Centrifuge the protein solution to remove insoluble material at 18,000 x g for 20 min at 4 °C. After the spin, transfer the supernatant to a new tube and place the tube on ice.
5. Prepare four volumes (60 ml) of refolding buffer (25 mM Tris, pH 9.0, 0.3 mM cystine, 3.0 mM cysteine, 1 mM EDTA). Degas the refolding buffer. Also prepare 600 μl 10 mM retinol in ethanol under dim red light. Keep it in the dark on ice. Both the refolding buffer and retinol solution need to be freshly prepared.
6. Cool both the protein solution and the refolding buffer on ice for at least 30 min. Higher temperature likely reduces the quality of refolded RBP. Add 1 ml refolding buffer dropwise and 10 μl retinol solution in turn while protein solution is vigorously mixed in a beaker on ice. Repeat this step until all refolding buffer and retinol are added. Keep stirring the reaction on ice in the dark for 5 hr.
7. Spin down the refolding reaction at 24,000 x g for 30 min at 4 °C. It is essential to remove the aggregates right after the refolding reaction.
8. Concentrate the supernatant solution using Amicon Ultra 15 concentrator (MWCO 10 K) to about 10 ml. Do not concentrate the refolded solution more than this level. Concentrating too much will lead to protein aggregation and lowers the final yield and quality of correctly folded RBP. Dilute the concentrated sample with cold PBS to 100 ml. The purpose of this step is to remove the components in the refolding reaction that interfere with nickel purification.
9. Spin the solution one more time at 24,000 x g for 20 min at 4 °C. It is important to remove any precipitate. Transfer the supernatant to two 50 ml tubes, each containing 1 ml Ni-NTA slurry that has been washed with PBS. Rotate the tubes at 4 °C for one hour. Incubating diluted solution for 1 hr can cause the precipitation of misfolded proteins which need to be removed.
10. Spin down the tubes at 500 x g for 3 min. Remove supernatant carefully. Anything floating should be removed. Add cold PBS to 30 ml for each tube. Spin again and remove the supernatant. Repeat this process until you see nothing but beads in the tube.
11. Transfer the Ni-NTA resin to an empty column. Wash resin with 20 column volumes of 10 mM imidazole, 500 mM NaCl in PBS. Elute His-RBP in 5 column volumes of 100 mM imidazole in PBS. Do not store this solution for an extended period of time, and freezing reduces the final yield and quality. For the best result, purify RBP by HPLC immediately.
12. Dialyze His-RBP purified from the Ni-NTA resin against 25 mM Tris, pH 8.4, and 120 mM NaCl. A concentrator can also be used for buffer exchange. Clear samples for HPLC by centrifugation at 16,000 x g for 10 min at 4 °C right before each run.
13. Purify holo-RBP on HPLC using an ion exchange column AX-300 by a NaCl step gradient (220 mM 12 min, 360 mM 15 min, and 1,000 mM 15 min) using 25 mM Tris, pH 8.4 as mobile phase at 1 ml/min. As NaCl concentration rises, holo-His-RBP is released while apo-RBP and misfolded RBP stay bound to the column (Figure 1). If RBP refolding is not done optimally, misfolded RBP (e.g. misfolded RBP-I in Figure 1) can predominate the whole preparation.
14. Recover the correctly folded holo-RBP from the peak fractions at 360 mM NaCl. Carefully monitor the elution profile of correctly folded and misfolded His-RBP. At 1,000 mM NaCl, most of misfolded His-RBP should be released.
15. Fractions containing holo-RBP are pooled, concentrated, and dialyzed against PBS overnight at 4 °C. Check the final yield and quality (330 nm/280 nm) by spectrophotometer. Correctly folded product should have a 330 nm/280 nm ratio of slightly higher than 1 (Figure 1).
16. To produce apo-RBP, add an equal volume of heptane to the purified holo-RBP and mix gently by rotating overnight at 4 °C. Centrifuge at 16,000 g for 10 min at 4 °C and carefully transfer the bottom aqueous phase to a new tube (avoiding the precipitate at the interface). Repeat the process three times with a 3 hr incubation for each. Check absorption on a Nanodrop spectrophotometer to make sure the 330 nm peak has decreased to the background level.

2. Real-time Monitoring of STRA6-catalyzed Retinol Release and Retinol Loading

1. Block a black 96-well Microfluor-2 plate (Thermo Scientific) with 200 μl of Blocker Casein (Pierce) overnight at 4 °C to prevent nonspecific sticking of holo-RBP to the plastic. Blocker Casein gives the best blocking effect of the all the blocking solutions we tested.
2. Membranes freshly prepared from cells expressing STRA6 or control cells are washed using PBS and passed through a Hamilton syringe (Gastight #1710) 6 times to produce a uniform suspension in PBS. We typically use membranes derived from 1/100 to 1/20 of cells grown on a 100 mm dish per reaction.
3. Wash the coated wells of the Microfluor-2 plate once with 200 μl of PBS. Cool the plate on ice before addition of membrane suspension (50 μl per well).
4. Real time monitoring of retinol fluorescence is measured using fluorescence optics of the POLARstar Omega (BMG Labtech) with the excitation filter 320ex and the emission filter 460-10. The program is set to the Endpoint reading mode. The Plate Mode can also be used to measure a time course if the time intervals are not varied. The signal from each time point is the average of 10 measurements (orbital averaging with a diameter of 2 mm) and the gain is set at 1,800. The plate is shaken for 10 sec at 500 rpm using double-orbital shaking before each measurement.
5. To start the retinol release assay, the wells are read once using the Endpoint reading mode before holo-RBP (typically 1 μM final concentration) is added at 0 min. As soon as holo-RBP is added, the reaction is monitored continuously every 5-10 min for 1-3 hr. To start the retinol loading assay, all-trans retinol (typically 1 μM final concentration) is added to the wells under dim red light. The plate is read once before apo-RBP is added at 0 min. As soon as apo-RBP is added, the reaction is monitored continuously every 5-10 min for 1-3 hr.
6. After all measurements are done, download the raw data (example shown in Figure 2) from the Omega Data Analysis software (BMG Labtech) to Microsoft Excel for data analysis. Each time point generates a file that contains the readings of all experimental conditions. For example, if there are 20 time points, consolidate 20 files into one Excel file for data analysis.
7. For data analysis, the fluorescence signals before the addition of retinol or holo-RBP at 0 min are considered background signals and subtracted from the final fluorescence signals at all time points. Although the background signals are low compared to retinol fluorescence in holo-RBP, subtracting the background eliminates the nonspecific influence of light scattering by the membranes and makes it possible to focus on the retinol fluorescence of holo-RBP or retinol added at 0 min.

3. Real-time Monitoring of STRA6-catalyzed Transport of Retinol From Holo-RBP to CRBP-I

1. Retinol-EGFP is a new fluorescence resonance transfer (FRET) pair that has recently been established ⁴¹. STRA6-catalyzed retinol transport from holo-RBP to EGFP-CRBP-I is monitored in real time by measuring retinol-EGFP FRET. EGFP-CRBP-I fusion protein with 6XHis tag (EGFP-CRBP-I) is produced in mammalian cells and is purified on Ni-NTA resin before the experiment. EGFP-CRBP-I can be stored in PBS with protease inhibitors for a short period of time at 4 °C. Alternatively the fusion protein is frozen in -80 °C in small aliquots.
2. Before the reactions, prepare a blocked Microfluor-2 plate and membranes as described above. Wash the coated wells of the Microfluor-2 plate once with 200 μl PBS before addition of membrane suspension (50 μl per well).
3. Real-time retinol-EGFP FRET is measured using POLARstar Omega with the excitation filter 320ex and the emission filters 460-10 and 510-10 using simultaneous duel emission fluorescence optics. The program is set to the Endpoint reading mode. The Plate Mode can also be used to measure a time course if the time intervals are not varied. The signal from each time point is the average of 10 measurements (orbital averaging with a diameter of 2 mm) and the gain is set at 1,800 per channel. The plate is shaken for 10 sec at 500 rpm using double-orbital shaking before each measurement.
4. To start the reactions, EGFP-CRBP-I (typically 1 μM final concentration) is added to the wells. The plate is read once using the Endpoint reading mode before holo-RBP is added at 0 min. As soon as holo-RBP is added, the reaction is monitored continuously by measurement every 5-10 min for 1-2 hr.
5. After all measurements are done, download the raw data (example shown in Figure 3) from the Omega Data Analysis software to Microsoft Excel for data analysis as described above.
6. Retinol-EGFP FRET is calculated by the dynamic change in the ratio of the acceptor/donor emission peaks⁴⁷. The equation⁴¹ to calculate this ratio is [(510_t-510_b)/(460_t-460_b)], where 510_t, 510_b, 460_t, and 460_b represent emissions at 510 nm after initiation of the reaction (t=time point), at 510 nm before retinol or holo-RBP is added (b=background), at 460 nm after initiation of the reaction (t=time point), and at 460 nm before retinol or holo-RBP is added (b=background), respectively.

Results

We present here representative results for holo-RBP production and purification by HPLC (Figure 1), real-time analysis of STRA6-catalyzed retinol release from holo-RBP and retinol loading into apo-RBP (Figure 2) and real-time analysis of STRA6-catalyzed retinol transport from holo-RBP to EGFP-CRBP-I (Figure 3).

Without refolding, RBP produced in bacteria is almost completely misfolded due to the presence of many incorrect disulfide bonds. Ther...

Discussion

We share here an optimized RBP production protocol because RBP production and purification procedures are critical to generating correctly folded RBP. Given the possibility of misfolded RBP species and the presence of trace amounts of bacterial proteins even in HPLC purified bacteria-produced RBP, it is helpful to use native RBP from serum to confirm a conclusion related to RBP. Urine RBP, which is commercially available, is a complex mixture of many species of RBP including apo-RBP and holo-RBP ^48,49.

Materials

List of materials used in this article

Name	Company	Catalog Number	Comments
guanidine hydrochloride	EMD	5010
cystine	Sigma	C8755
cysteine	Sigma	C7352
EDTA	Fisher	BP118-500
Tris	Fisher	7786-1
DTT	EMD	3860
retinol	Sigma	R7632
carbenicillin	Fisher	BP2648-5
IPTG	EMD	5810
PBS	EMD	6508
NaCl	Fisher	BP358-10
Ni-NTA	Qiagen	1018244
imidazole	EMD	5720
heptane	EMD	HX0295-1
Blocker Casein	Pierce	37528
Amicon Ultra 15 concentrator (MWCO 10 K)	Millipore	UFC901024
Microfluor-2 plate	Fisher	14-245-177
Hamilton syringe Gastight #1710	Fisher	14-824-655